• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Unveiling post-vaccination proteomic signatures in SARS-CoV-2 infection-naïve individuals associated with Omicron breakthrough infections

tetano

Editor, Senior Moderator
PLoS One


. 2026 May 11;21(5):e0347602.
doi: 10.1371/journal.pone.0347602. eCollection 2026.
Unveiling post-vaccination proteomic signatures in SARS-CoV-2 infection-naïve individuals associated with Omicron breakthrough infections

Yiwen Liu[SUP] 1 [/SUP], Eric Lu[SUP] 2 [/SUP], Katherine D Ellingson[SUP] 1 [/SUP], James Hollister[SUP] 1 [/SUP], Tuo Liu[SUP] 3 [/SUP], Wadana Hamzazai[SUP] 1 [/SUP], Shawn C Beitel[SUP] 3 [/SUP], Alberto J Caban-Martinez[SUP] 4 [/SUP], Manjusha Gaglani[SUP] 5 [/SUP], Allison L Naleway[SUP] 6 [/SUP], Lauren E W Olsho[SUP] 7 [/SUP], Andrew L Phillips[SUP] 8 [/SUP], Natasha Schaefer Solle[SUP] 9 [/SUP], Harmony L Tyner[SUP] 10 [/SUP], Sarang K Yoon[SUP] 8 [/SUP], Karen Lutrick[SUP] 11 [/SUP], Jefferey L Burgess[SUP] 3 [/SUP]


Affiliations
Abstract

Background: Given the persistence of the SARS-CoV-2 virus, it is important to understand the proteome associated with breakthrough infections among COVID-19 vaccinated individuals.
Methods: We conducted a nested case-control study within the frontline worker HEROES-RECOVER cohorts to specify a study population of SARS-CoV-2 infection-naïve participants who had a third dose of COVID-19 origin strain WA-1 monovalent mRNA vaccine from August 2021 to January 2022. We compared serum proteomic profiles for those who subsequently experienced Omicron breakthrough infections with those of matched controls without infections. Our study leveraged proteomics data generated from the SomaScan Platform and adopted a robust feature selection method, elastic net regularized conditional logistic regression with bootstrapping, to identify key proteins. Enrichment analyses were performed to investigate biological pathways.
Results: We identified 28 significant proteins out of over 7,000 candidate proteins. Key findings included downregulated chemokines (CXCL2, CXCL3, CCL19, CCL23) and elevated cytokine IL-7 levels in breakthrough cases, with pathway analysis revealing enrichment in chemokine signaling and cytokine-cytokine interaction pathways. Other key proteins, such as LGALS1, HAVCR2, and SELE were upregulated in breakthrough cases.
Discussion: These results reveal potential immune response mechanisms in breakthrough infections, characterized by viral immune evasion and compensatory T-cell regeneration. The identified biomarkers may provide valuable insights for future predictive profiles and therapeutic strategies.


 
Back
Top